HDACi I and J are non-hydroxamate HDAC6 inhibitors designed to avoid the genotoxicity commonly associated with hydroxamates and are optimized for central nervous system disorders with enhanced brain accessibility [27]. The gene discussed is HDAC6; the disease is central nervous system disorder.